Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2026

The vascular endothelial growth factor (vegf) inhibitor market size has grown strongly in recent years. It will grow from $11.3 billion in 2025 to $12.11 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising incidence of cancer and retinal disorders, limited treatment options before monoclonal antibodies, growing awareness of anti-angiogenic therapy benefits, increasing physician adoption of targeted therapies, regulatory approvals of first-generation vegf inhibitors.

The vascular endothelial growth factor (vegf) inhibitor market size is expected to see strong growth in the next few years. It will grow to $16.23 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to development of next-generation vegf inhibitors, expansion in immuno-oncology combinations, increasing adoption of personalized medicine, rising investments in ophthalmic drug development, integration of digital monitoring and AI-based treatment assessment. Major trends in the forecast period include rising adoption of vegf inhibitors in oncology and ophthalmology, increasing development of monoclonal antibodies and anti-angiogenic therapies, growth in intravitreal and intravenous administration routes, expansion of personalized medicine and targeted therapy approaches, increasing clinical trials and research for novel vegf inhibitors.

The increasing prevalence of cancer and macular degeneration is anticipated to drive the growth of the VEGF inhibitor market in the coming years. Cancer is a condition characterized by the uncontrolled growth of abnormal cells that can spread to other parts of the body, while macular degeneration is a disorder that causes deterioration of the central region of the retina, leading to vision impairment. The rising occurrence of these conditions is driven by factors such as an aging population and lifestyle-related risks, resulting in greater demand for effective treatment options and healthcare interventions. Vascular endothelial growth factor (VEGF) inhibitors help address cancer by preventing the formation of new blood vessels required for tumor growth and spread, thereby limiting tumor progression and metastasis. For example, in February 2024, according to the World Health Organization, a Switzerland-based international organization focused on global health policy and public health initiatives, more than 35 million new cancer cases are projected by 2050, representing a 77% increase from the estimated 20 million cases reported in 2022. Therefore, the rising prevalence of cancer and macular degeneration is contributing to the growth of the VEGF inhibitor market.

Key companies operating in the VEGF inhibitor market are emphasizing the development of advanced ophthalmic therapies, including higher-concentration intravitreal injection formulations designed to extend dosing intervals and minimize treatment burden for patients. Higher-concentration intravitreal injection solutions contain increased levels of the active drug per dose, allowing for fewer injections while preserving therapeutic effectiveness and reducing patient burden. For instance, in April 2024, Santen Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, in collaboration with Bayer Yakuhin, a Japan-based pharmaceutical and life sciences company, launched the ophthalmic VEGF inhibitor Eylea 8 mg solution for intravitreal injection at a concentration of 114.3 mg/mL. These therapies are standard treatments for conditions such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both of which can lead to vision loss. Eylea 8 mg, featuring a higher concentration than earlier versions, enables an extended dosing interval of up to 16 weeks, decreasing the frequency of intravitreal injections while maintaining safety and efficacy. This innovation is intended to reduce the treatment burden on patients and establish a new standard of care, while also supporting the strategic goal of expanding access to this advanced ophthalmic therapy.

In January 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, acquired the worldwide license for fruquintinib, a highly selective oral VEGFR1/2/3 tyrosine kinase inhibitor, from HUTCHMED Limited for an undisclosed sum. Under the terms of the agreement, Takeda obtained exclusive global rights to develop and commercialize fruquintinib for all indications and regions outside mainland China, Hong Kong, and Macau. HUTCHMED Limited is a China-based pharmaceutical company specializing in the development of vascular endothelial growth factor receptor (VEGFR) 1/2/3-targeted therapies.

Major companies operating in the vascular endothelial growth factor (vegf) inhibitor market are F. Hoffmann-La Roche AG, Bayer AG, Regeneron Pharmaceuticals Inc., AstraZeneca Plc., Novartis AG, Pfizer Inc., Eli Lilly and Company, Exelixis Inc., Amgen Inc., Sanofi S.A., Cipla Limited, Biocon, Dr. Reddy's Laboratories, Innovent Biologics, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Ipsen, Oxurion, Pharmstandard Group, Zentiva, Coherus BioSciences Inc., AVEO pharmaceuticals, Eisai Co. Ltd.

North America was the largest region in the vascular endothelial growth factor (VEGF) inhibitor market in 2025. Middle East is expected to be the fastest-growing region in the vascular endothelial growth factor (VEGF) inhibitor market share during the forecast period. The regions covered in the vascular endothelial growth factor (vegf) inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vascular endothelial growth factor (vegf) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the VEGF inhibitor market by increasing the cost of imported biologics, monoclonal antibodies, and administration devices, affecting supply chains and treatment affordability. Segments like oncology and ophthalmology drugs are most affected, particularly in North America and Europe, which rely heavily on imports. While tariffs have raised treatment costs and caused potential delays in therapy availability, they have also encouraged local manufacturing, investment in domestic R&D, and innovation in cost-effective VEGF inhibitor therapies.

The vascular endothelial growth factor (vegf) inhibitor market research report is one of a series of new reports that provides vascular endothelial growth factor (vegf) inhibitor market statistics, including vascular endothelial growth factor (vegf) inhibitor industry global market size, regional shares, competitors with a vascular endothelial growth factor (vegf) inhibitor market share, detailed vascular endothelial growth factor (vegf) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the vascular endothelial growth factor (vegf) inhibitor industry. This vascular endothelial growth factor (vegf) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A VEGF inhibitor is a substance that blocks programmed cell death by functioning as an anti-apoptotic factor for hematopoietic cells. VEGF enhances vascular permeability, which can facilitate tumor spread through the bloodstream and support increased oxygen and nutrient supply to tumors.

The primary types of vascular endothelial growth factor (VEGF) inhibitors include Avastin, Tecentriq, Cometriq, Eylea, and others. Avastin is a drug used to treat wet age-related macular degeneration (AMD) and is also applied in managing diabetic eye diseases and other retinal disorders. It is injected into the eye to help slow vision loss associated with specific conditions. These inhibitors are administered through oral and intravenous routes and are used across applications such as oncology, ophthalmology, and others.

The vascular endothelial growth factor (VEGF) inhibitor market consists of sales of nexavar, sunitinib, nilotinib, pazopanib, and dasatinib. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.